Tirzepatide activates both the GLP-1 and GIP receptors — two of the body’s natural appetite and blood-sugar hormones. It slows gastric emptying so food stays longer, signals fullness to the brain so cravings quiet down, and improves insulin response. The clinical-trial data showing ~20% body-weight loss is from the FDA-approved brand-name versions (Zepbound, Mounjaro); compounded formulations are not FDA-reviewed.

Same active molecule, different supply chain. Zepbound and Mounjaro are FDA-approved brand-name medications made by Eli Lilly. Compounded tirzepatide is prepared by independent state-licensed US compounding pharmacies on a patient-specific prescription under section 503A. Compounded drugs are not FDA-approved and are not interchangeable with the brand. Your provider will help you decide which is right.

Most men notice reduced appetite and quieter food noise inside the first one-to-two weeks. Mild nausea, fatigue, constipation, or heartburn are common as your body adjusts and usually fade as your dose stabilizes. The provider titrates you up slowly to minimize side effects. Message them through the patient portal anytime you have a question.

A once-weekly subcutaneous injection you give yourself at home. Takes under 30 seconds with a tiny needle most men barely feel. Your first shipment includes the vial, syringes, alcohol pads, and a step-by-step guide.

Do not use if you or a family member has medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), if you have a history of pancreatitis or severe gastrointestinal disease, or during pregnancy or breastfeeding. The provider screens for this during your intake.

Monthly plans are billed and shipped monthly. Quarterly plans are billed and shipped every 3 months. 6-month plans are billed every 6 months and shipped quarterly (2 shipments per billing cycle). Annual plans are billed once per year and shipped quarterly (4 shipments total). Every plan is paid upfront for its term.